Tubulin-targeted agents including docetaxel and cabazitaxel

Cancer Journal (United States)

Volumn 19, Issue 1, 2013, Pages 59-65

  Cheetham, Philippa ^a   Petrylak, Daniel P ^b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

cabazitaxel; docetaxel; epothilones; microtubules; taxanes; Tubulin; vinca alkaloids

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; ATRASENTAN; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; ERIBULIN; ESTRAMUSTINE; ESTRAMUSTINE PHOSPHATE; IXABEPILONE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; NARCOTIC ANALGESIC AGENT; PACLITAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; TESTOSTERONE; TUBULIN; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BONE PAIN; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CASTRATION RESISTANT PROSTATE CANCER; CELL DEATH; CELLULAR DISTRIBUTION; CONTINUOUS INFUSION; CYTOTOXICITY; DEEP VEIN THROMBOSIS; DEPOLYMERIZATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLUID RETENTION; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOHISTOCHEMISTRY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS; TUBULIN MODULATORS;

EID: 84873840112     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3182828d38     Document Type: Review

References (62)

1. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramus-tine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
3. Haldar S, Chintapalli J, Croce CM. Taxol induces Bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 1996;56:1253-1255.
4. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA. 1995;92:4507-4511.
5. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res. 1997;57:229-233.
6. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the proto-oncogene Bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992;52:6940-6944.
7. Gan L, Chen S, Wang Y, et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res. 2009;69:8386-8394.
8. Kuroda K, Liu H, Kim S, et al. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate. 2009;69:1579-1585.
9. Zhu ML, Horbinski CM, Garzotto M, et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010;70:7992-8002.
10. Darshan MS, Loftus MS, Thadani-Mulero M, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 2011; 71:6019-6029.
11. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005.
12. Ryan CJ, Smith MR, De Bono JS, et al. Interim analysis results of COU-302, a randomized phase III study of abiraterone acetate (AA) in chemotherapy naive patients (pts) with metastatic castration resistant prostate cancer (CRPC). J Clin Oncol. 30.
13. NCCN Clinical Practice Guidelines: Prostate Cancer. Fort Washington, PA: National Comprehensive Cancer Network; 2011:1-69.
14. Mezynski J, Pezaro C, Bianchini D, et al. Antitumour activity of doce-taxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol. 2012;23:2943-2947.
15. Montgomery RB, Bonham M, Nelson PS, et al. Estrogen effects on tu-bulin expression and taxane mediated cytotoxicity in prostate cancer cells. Prostate. 2005;65:141-150.
16. Mohan R, Panda D. Kinetic stabilization of microtubule dynamics by estramustine is associated with tubulin acetylation, spindle abnormalities, and mitotic arrest. Cancer Res. 2008;68:6181-6189.
17. Mareel MM, Storme GA, Dragonetti CH, et al. Antiinvasive activity of estramustine on malignant MO4 mouse cells and on DU-145 human prostate carcinoma cells in vitro. Cancer Res. 1988;48:1842-1849.
18. Seidman AD, Scher HI, Petrylak D, et al. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol. 1992;147:931-934.
19. Hudes GR, Greenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol. 1992;10:1754-1761.
20. Amato RJ, Ellerhorst J, Bui C, et al. Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate. Urol Oncol. 1995;1:168-172.
21. Hudes G, Einhorn L, Ross E, et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol. 1999;17:3160-3166.
22. Spencer CM, Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs. 1994;48:794-847.
23. Roth BJ, Yeap BY, Wilding G, et al. Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer. 1993;72:2457-2460.
24. Speicher LA, Barone L, Tew KD. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res. 1992;52:4433-4440.
25. Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1997;15:3156-3163.
26. Berry WR, Hathorn JW, Dakhil SR, et al. Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer. Clin Prostate Cancer. 2004;3:104-111.
27. Bissery MC, Nohynek G, Sanderink GJ, et al. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs. 1995;6:339-355, 63-68.
28. Petrylak DP, Macarthur RB, O'Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 1999;17:958-967.
29. Kreis W, Budman DR, Fetten J, et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol. 1999; 10:33-38.
30. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol. 1999;26:14-18.
31. Friedland D, Cohen J, Miller R Jr, et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitu-mor effect to phosphorylation of Bcl-2. Semin Oncol. 1999;26:19-23.
32. Berry W, Dakhil S, Gregurich MA, et al. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol. 2001;28:8-15.
33. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242-245.
34. Berry DL, Moinpour CM, Jiang CS, et al. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol. 2006;24:2828-2835.
35. Berthold DR, Pond GR, Roessner M, et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res. 2008;14:2763-2767.
36. Berthold DR, Pond GR, de Wit R, et al. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol. 2008;19:1749-1753.
37. Fizazi K, Le Maitre A, Hudes G, et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol. 2007; 8:994-1000.
38. Quinn DI TC, Hussain M, Lara P, et al. SWOG S0421: phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC). J Clin Oncol. 2012;30. Abstract 4511.
39. Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and predni-sone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30:1534-1540.
40. Petrylak DP, Fizazi K, Sternberg CN, et al. Phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone (DP) with or without lenalidomide (LEN) in patients with castrate-resistant prostate cancer (CRPC): the MAINSAIL Trial PROC ESMO 2012:LBA24.
41. Scher HI, Jia X, Chi K, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol. 2011;29: 2191-2198.
42. Goldkorn A, Ely B, Quinn DI, et al. SWOG 0421: prognostic and predictive value of bone metabolism biomarkers (BMB) in castration resistant prostate cancer (CRPC) patients (pts) with skeletal metastases treated with docetaxel (DOC) with or without atrasentan (ATR). J Clin Oncol. 2012;30. Abstract 4547.
43. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothi-lone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001;7:1429-1437.
44. Lee JJ, Swain SM. The epothilones: translating from the laboratory to the clinic. Clin Cancer Res. 2008;14:1618-1624.
45. Hussain M, Tangen CM, Lara PN Jr, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol. 2005;23:8724-8729.
46. Liu G, Chen YH, Dipaola R, et al. Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group. Clin Genitourin Cancer. 2012;10:99-105.
47. Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol. 2005;23:1439-1446.
48. Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007;110:556-563.
49. O'Reilly T, McSheehy PM, Wenger F, et al. Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo. Prostate. 2005;65:231-240.
50. Hussain A, DiPaola RS, Baron AD, et al. Phase II trial of weekly patu-pilone in patients with castration-resistant prostate cancer. Ann Oncol. 2009;20:492-497.
51. Chi KN, Beardsley E, Eigl BJ, et al. A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. Ann Oncol. 2012;23:53-58.
52. Beer TM, Smith DC, Hussain A, et al. Phase II study of first-line sago-pilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium. Br J Cancer. 2012;107:808-813.
53. Preston JN, Trivedi MV. Eribulin: a novel cytotoxic chemotherapy agent. Ann Pharmacother. 2012;46:802-811.
54. Swami U, Chaudhary I, Ghalib MH, et al. EribulinVa review of preclin-ical and clinical studies. Crit Rev Oncol Hematol. 2012;81:163-184.
55. de Bono JS, Molife LR, Sonpavde G, et al. Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Ann Oncol. 2012;23:1241-1249.
56. Kawai K, Sakurai M, Sakai T, et al. Demonstration of MDR1 P-glycoprotein isoform expression in benign and malignant human prostate cells by isoform-specific monoclonal antibodies. Cancer Lett. 2000;150: 147-153.
57. Henson JW, Cordon-Cardo C, Posner JB. P-glycoprotein expression in brain tumors. J Neuro-oncol. 1992;14:37-43.
58. Bissery MC. Preclinical evaluation of new taxoids. Curr Pharm Des. 2001;7:1251-1257.
59. Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15:723-730.
60. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147-1154.
61. De Bono JS, Ouclard M, Ozguroglu S, et al. A subgroup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and survival outcome of cabazitaxel in metastatic castration resistent prostate cancer (mCRPC). J Clin Oncol. 2011;29.(suppl). Abstract 4526.
62. Sartor AO, Oudard S, Ozguroglu M, et al. Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mito-xantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial. J Clin Oncol. 2011;29. Abstract 4525.